Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.

91 There was a trend for a modest additional total body weight loss in the combination group compared to liraglutide and placebo group, but the difference did not reach statistical significance (difference 1.4 (−0.1 to 3.0) %, p 0.073). 91 Interestingly, hunger was significantly lower in the former compared to the latter group. 91 The most common adverse events were musculoskeletal and gastroesophageal reflux, without a significantly increased risk of hypertension or palpitations. 91 A 26

also in 111,027 other papers